BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia, the identification of BCR-ABL fusion gene, which leads to overproduction of a growth-stimulatory tyrosine kinase, led to the development of targeted TKIs with imatinib targeting BCR-ABL as the first.